Peripheral Neuropathy Treatment Market By Product Type (Prescription Medications, Over-the-Counter Medications, Medical Devices), By Treatment Type (Pharmacological Treatment, Non-pharmacological Treatment, Physical Therapy), By End-User (Hospitals & Clinics, Home Healthcare Providers, Research Institutes), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peripheral Neuropathy Treatment Market was valued at USD 7.4 billion in 2024-e and will surpass USD 12.6 billion by 2030; growing at a CAGR of 9.2% during 2025 - 2030.

The peripheral neuropathy treatment market is experiencing steady growth due to the increasing prevalence of peripheral neuropathy, a condition that affects the peripheral nerves and is often associated with underlying conditions such as diabetes, infections, and autoimmune diseases. As the global population ages, the incidence of conditions like diabetes, which are linked to peripheral neuropathy, is rising, leading to a greater demand for effective treatments. Advances in medical research have also resulted in the development of new therapeutic options that improve patient outcomes, driving the growth of this market.

The market is characterized by a combination of pharmacological and non-pharmacological treatments, with the choice of treatment depending on the severity of the condition and the underlying cause of the neuropathy. Prescription medications remain the primary form of treatment, often used in conjunction with physical therapy and medical devices for enhanced patient recovery. With increasing awareness of peripheral neuropathy and advancements in treatment options, the market is poised for continued expansion, particularly in regions with aging populations and rising chronic disease burdens.

Prescription Medications Segment is Largest Product Type Owing to Efficacy in Managing Symptoms

The prescription medications segment holds the largest share in the peripheral neuropathy treatment market, owing to the effectiveness of these drugs in managing the symptoms of the condition. Prescription medications, such as pain relievers, anticonvulsants, and antidepressants, are commonly used to alleviate the burning, tingling, and numbness associated with peripheral neuropathy. These drugs are highly effective in controlling pain, improving quality of life, and addressing the underlying causes of neuropathy when appropriate.

The demand for prescription medications continues to grow due to their proven efficacy in treating various forms of peripheral neuropathy, including diabetic neuropathy and chemotherapy-induced neuropathy. Additionally, as research into neuropathic pain progresses, new and more effective medications are being introduced, further driving the growth of this segment. Patients often prefer prescription medications as they provide targeted relief and are prescribed by healthcare professionals who tailor the treatment plan to individual needs.

Non-pharmacological Treatment Segment is Fastest Growing Segment Owing to Increasing Awareness and Alternative Approaches

The non-pharmacological treatment segment is the fastest-growing segment in the peripheral neuropathy treatment market, driven by increasing patient awareness and the demand for alternative treatment options. Non-pharmacological treatments, such as acupuncture, transcutaneous electrical nerve stimulation (TENS), and dietary supplements, are gaining popularity as adjuncts to pharmacological treatments. These treatments are often used by patients seeking to avoid the side effects associated with prescription medications or as complementary therapies to enhance the effects of traditional treatments.

Physical therapy is another key non-pharmacological treatment that is gaining traction in the management of peripheral neuropathy. It helps improve muscle strength, balance, and coordination, which can be impaired by neuropathy. Non-pharmacological treatments are seen as holistic approaches to managing peripheral neuropathy and are often recommended by healthcare providers in conjunction with pharmacological treatments for comprehensive symptom management.

Hospitals & Clinics Segment is Largest End-User Owing to High Volume of Cases and Specialized Care

Hospitals and clinics are the largest end-users in the peripheral neuropathy treatment market, owing to the high volume of cases treated in these settings. Hospitals and clinics are equipped with advanced diagnostic tools and specialized healthcare providers who are capable of accurately diagnosing the underlying causes of peripheral neuropathy and tailoring treatment plans accordingly. These facilities are the primary locations where patients receive comprehensive care for peripheral neuropathy, including medication management, physical therapy, and medical devices.

The increasing prevalence of chronic conditions such as diabetes and cancer, both of which are closely linked to peripheral neuropathy, further contributes to the high demand for treatment in hospitals and clinics. The availability of multidisciplinary care teams and the ability to monitor patients’ progress in a clinical setting make hospitals and clinics the most common point of care for individuals suffering from peripheral neuropathy.

Physical Therapy Segment is Largest Treatment Type Owing to Effectiveness in Symptom Management

Physical therapy is the largest treatment type segment in the peripheral neuropathy treatment market, as it is a key component in managing the symptoms of peripheral neuropathy. Physical therapy helps patients strengthen their muscles, improve their balance, and regain coordination, all of which can be affected by neuropathy. This type of therapy is particularly beneficial for patients with diabetic neuropathy, which often leads to muscle weakness and loss of coordination.

Physical therapy can also be used to address pain and discomfort associated with peripheral neuropathy. Many patients with peripheral neuropathy benefit from physical therapy in combination with pharmacological treatments to achieve the best possible outcomes. The segment’s growth is further supported by the increasing adoption of physical therapy as a standard part of neuropathy management plans, as it is considered a non-invasive and effective treatment option.

North America is Largest Region Owing to Advanced Healthcare Infrastructure and High Prevalence of Chronic Conditions

North America is the largest region in the peripheral neuropathy treatment market, primarily due to the advanced healthcare infrastructure in the United States and Canada, along with the high prevalence of chronic conditions such as diabetes, which is a leading cause of peripheral neuropathy. The region has a well-established healthcare system that facilitates access to cutting-edge treatments, including prescription medications, non-pharmacological treatments, and physical therapy.

The aging population in North America also plays a key role in the growth of the peripheral neuropathy treatment market, as age-related conditions are major contributors to neuropathy. Furthermore, rising awareness about peripheral neuropathy and its treatments, as well as an increasing number of healthcare providers specializing in pain management and neurological disorders, are driving market growth in the region. North America’s dominant position is expected to continue, as ongoing advancements in neuropathy treatments and medical research offer new avenues for managing this condition.

Competitive Landscape

The peripheral neuropathy treatment market is highly competitive, with several key players leading the development of innovative treatments. Pharmaceutical companies are focusing on expanding their portfolios with new medications, while medical device manufacturers are working on developing advanced devices that can help manage neuropathy symptoms more effectively. Companies are also investing in research and development to better understand the underlying mechanisms of neuropathy and create more targeted therapies.

Strategic partnerships, acquisitions, and collaborations are common in this market, as companies seek to enhance their product offerings and expand their market presence. The increasing focus on personalized treatment plans, which combine pharmacological, non-pharmacological, and physical therapy approaches, is likely to result in further market growth and innovation. As demand for more effective treatments continues to rise, the competitive landscape will remain dynamic, with companies vying to offer comprehensive and effective solutions for patients suffering from peripheral neuropathy.

List of Leading Companies:

• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline
• Merck & Co., Inc.
• Eli Lilly and Co.
• Abbott Laboratories
• Novartis
• Astellas Pharma Inc.
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila
• Endo Pharmaceuticals
• Sanofi
• Amgen Inc.
• Regeneron Pharmaceuticals
• Medtronic

Recent Developments:

• In December 2024, Pfizer Inc. launched a new neuropathy pain relief drug specifically targeting diabetic neuropathy.
• In November 2024, Johnson & Johnson introduced a new over-the-counter treatment for mild peripheral neuropathy.
• In October 2024, Merck & Co., Inc. received approval for a new non-opioid pain management device for neuropathy treatment.
• In September 2024, Eli Lilly and Co. announced the release of a new neuropathy treatment focused on nerve regeneration.
• In August 2024, Abbott Laboratories expanded its product line with a new device for non-pharmacological peripheral neuropathy therapy.

Report Scope: